A provider-focused briefing on the Cipro (Ciprofloxacin) shortage in 2026: timeline, prescribing implications, alternatives, cost, and tools to help your patients.
Ciprofloxacin remains one of the most prescribed fluoroquinolone antibiotics in the United States, with indications spanning urinary tract infections, respiratory infections, bone and joint infections, GI infections, and anthrax prophylaxis. Over the past several years, supply disruptions — particularly in the IV formulation — have forced clinicians to rethink prescribing patterns and patient counseling around this workhorse antibiotic.
This briefing provides an up-to-date overview of the Ciprofloxacin supply landscape in 2026, along with practical guidance for prescribers navigating availability challenges.
Reports of intermittent Ciprofloxacin injection supply tightness began surfacing in late 2022, driven by manufacturing capacity constraints among the small number of IV Ciprofloxacin producers.
The most significant event was Baxter's discontinuation of its Ciprofloxacin injection product in January 2023. Baxter was a major supplier to hospitals and health systems nationwide. This exit immediately strained the remaining manufacturers — primarily Fresenius Kabi and Hikma — and triggered ASHP to list Ciprofloxacin injection on its current drug shortage database.
Throughout 2023 and into 2024, the remaining manufacturers worked to increase production capacity. The FDA worked with manufacturers to expedite approvals and resolve supply chain bottlenecks. Hospitals implemented conservation strategies, including earlier IV-to-oral conversion protocols and therapeutic substitution guidelines.
By 2025, the IV shortage had largely stabilized, though intermittent supply tightness persists in some regions and hospital systems. Oral Ciprofloxacin (tablets and suspension) has maintained generally adequate supply throughout this period, produced by multiple generic manufacturers.
The Cipro supply situation has several practical implications for prescribers:
The IV shortage has reinforced the importance of early IV-to-oral conversion. Ciprofloxacin has excellent oral bioavailability (approximately 70-80%), making oral therapy appropriate for most patients who can tolerate PO medications. Current antimicrobial stewardship guidelines strongly support converting to oral therapy as soon as clinically appropriate.
The FDA's ongoing safety communications regarding fluoroquinolones — including the Boxed Warning for tendinitis, tendon rupture, peripheral neuropathy, and CNS effects — continue to narrow appropriate use. Reserve Ciprofloxacin for infections where benefits clearly outweigh risks, particularly in:
Ciprofloxacin has clinically significant interactions that impact prescribing decisions. For a comprehensive reference, see: Cipro Drug Interactions: What to Avoid. Key interactions include:
Oral formulations: Ciprofloxacin 250 mg, 500 mg, and 750 mg immediate-release tablets are produced by multiple generic manufacturers and are generally well-stocked at retail and mail-order pharmacies. Extended-release Ciprofloxacin (Cipro XR) 500 mg and 1000 mg tablets are also available for UTI indications. Oral suspension (5% and 10%) may be less consistently stocked, particularly at smaller pharmacies.
IV formulations: Ciprofloxacin injection supply has improved but remains concentrated among fewer manufacturers than pre-2023 levels. Hospital pharmacies should maintain appropriate par levels and have IV-to-oral conversion protocols in place.
Topical formulations: Ciprofloxacin otic (Cetraxal) and ophthalmic (Ciloxan) formulations have not experienced significant supply issues.
Cost is rarely a barrier for oral Ciprofloxacin. Generic pricing is among the lowest for any antibiotic:
For patients who report cost concerns, discount programs from SingleCare, GoodRx, and others can reduce prices to well under $15. The Bayer Patient Assistance Foundation provides qualifying medications at no cost for uninsured patients.
For detailed patient-facing savings information: How to Save Money on Cipro in 2026.
Several tools can help you and your patients navigate Cipro availability:
When Ciprofloxacin is unavailable or contraindicated, consider these evidence-based alternatives by indication:
For a patient-friendly comparison: Alternatives to Cipro If You Can't Fill Your Prescription.
The fluoroquinolone landscape continues to evolve. Key trends to watch in 2026 and beyond:
Ciprofloxacin remains a valuable tool in the antimicrobial armamentarium, but the supply disruptions of recent years highlight the importance of prescriber awareness around availability, alternatives, and patient access tools. By staying informed about the current supply picture and leveraging tools like Medfinder for Providers, you can help ensure your patients receive timely, effective antibiotic therapy even when first-choice agents are temporarily unavailable.
For guidance on helping your patients locate medications, see: How to Help Your Patients Find Cipro in Stock: A Provider's Guide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
